Adult: As 0.05% cream, ointment, gel or solution: Apply thinly onto the affected area 2-4 times daily depending on the severity of the condition. May reduce dosage once improvement is observed. As 0.1% cream: Apply thinly onto the affected area once daily or bid for up to 2 weeks. Max total dose: 60 g weekly. Discontinue treatment when control is achieved; re-assess diagnosis if no response is evident within 2 weeks. Dosage or dosing frequency recommendations may vary among countries and between individual products (refer to local or specific product guidelines). Child: As 0.05% cream, ointment, gel or solution: Same as adult dose. Use the minimum effective dose and limit treatment to a short duration. As 0.1% cream: ≥12 years Same as adult dose. Treatment recommendations may vary among countries and between individual products (refer to local or specific product guidelines).
What are the brands available for Fluocinonide in Philippines?
Acne, rosacea, perioral dermatitis; bacterial, fungal, or viral infections of the skin.
Special Precautions
Patient with psoriasis. Avoid prolonged use, particularly on the face. Higher-strength preparation (0.1%) must not be used on the face, groin, or axillae. Children. Pregnancy and lactation.
Adverse Reactions
Significant: Hypercortisolism or HPA axis suppression (particularly in younger children or use of high doses for prolonged periods), manifestations of Cushing's syndrome, hyperglycaemia, glycosuria (following systemic absorption); local adverse reactions (e.g. skin atrophy, skin striae, dry skin, telangiectasia, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, miliaria, allergic contact dermatitis) that may occur with occlusive dressing and/or prolonged use; skin infections; growth inhibition (prolonged use in children); topical steroid withdrawal reactions (after discontinuation of ≥6 months long-term use), may be manifested as severe redness of the skin which may extend to areas beyond the initial affected area, burning or stinging sensation, itching, skin peeling, and oozing pustules. General disorders and administration site conditions: Irritation at the application site. Immune system disorders: Hypersensitivity. Skin and subcutaneous tissue disorders: Hypertrichosis.
Avoid contact with the eyes. Avoid use of tight-fitting diapers or plastic pants in children being treated in the diaper area. Do not use with occlusive dressings, particularly in children, unless directed by the doctor. For long-term use of ≥6 months: Inform the doctor immediately if severe redness which can spread beyond the initial affected area, itching, burning or stinging sensation, skin peeling, and oozing pustules occur after treatment discontinuation.
Monitoring Parameters
Evaluate for evidence of HPA axis suppression (e.g. ACTH stimulation test, urinary free cortisol test) in patients receiving large doses over a large surface area or under an occlusive dressing. Assess for signs and symptoms of bacterial or fungal infections; topical steroid withdrawal reactions (after treatment discontinuation of long-term use). Monitor growth in children (particularly during prolonged use).
Action
Description: Mechanism of Action: Fluocinonide is a potent fluorinated corticosteroid that has anti-inflammatory, antipruritic, and vasoconstrictive properties. It induces phospholipase A2 inhibitory proteins (lipocortins) and sequentially inhibits arachidonic acid release, thereby suppressing the formation, release, and activity of endogenous inflammatory mediators (e.g. kinins, histamine, liposomal enzymes, prostaglandins). Pharmacokinetics: Absorption: Absorbed percutaneously; extent of absorption may depend on the formulation, amount applied, integrity of the epidermal barrier, and use of occlusive dressings. Metabolism: Metabolised mainly in the liver. Excretion: Mainly via urine; bile.
Chemical Structure
Fluocinonide Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 9642, Fluocinonide. https://pubchem.ncbi.nlm.nih.gov/compound/Fluocinonide. Accessed Oct. 29, 2024.
Storage
Cream/Solution: Store below 30°C. Avoid excessive heat. Ointment/Gel: Store between 20-25 °C. Storage recommendations may vary between individual products (refer to specific product guidelines).
D07AC08 - fluocinonide ; Belongs to the class of potent (group III) corticosteroids. Used in the treatment of dermatological diseases.
References
Brayfield A, Cadart C (eds). Fluocinonide. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 17/09/2024.Fluocinonide Cream, Gel, and Ointment (Taro Pharmaceuticals U.S.A., Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 17/09/2024.Fluocinonide Solution (Macleods Pharmaceuticals Limited). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 25/10/2024.Fluocinonide. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com. Accessed 17/09/2024.Fluocinonide. UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 17/09/2024.Joint Formulary Committee. Fluocinonide. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 17/09/2024.Lidex Cream and Ointment (Interphil Laboratories, Inc.). MIMS Philippines. http://www.mims.com/philippines. Accessed 17/09/2024.Metosyn FAPG Cream (Reig Jofre UK Limited). MHRA. https://products.mhra.gov.uk. Accessed 17/09/2024.Metosyn Ointment (Reig Jofre UK Limited). MHRA. https://products.mhra.gov.uk. Accessed 17/09/2024.Topical Corticosteroids: Information on the Risk of Topical Steroid Withdrawal Reactions. Medicines & Healthcare products Regulatory Agency. https://www.gov.uk/drug-safety-update. Accessed 17/09/2024.Topical Steroids: Introduction of New Labelling and a Reminder of the Possibility of Severe Side Effects, Including Topical Steroid Withdrawal Reactions. Medicines & Healthcare products Regulatory Agency. https://www.gov.uk/drug-safety-update. Accessed 17/09/2024.Vanos Cream (Bausch Health US, LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 17/09/2024.
Sign Out
Continue with Google